

Liver function monitoring scheme with Agomelatine for the treatment of major depressive episodes in adults

Patient name: _____

Date of initiation: _____

Agomelatine 25mg


<input type="checkbox"/> Before Initiation of 25mg	ALTU/L
	ASTU/L
<input type="checkbox"/> Week 3	ALTU/L
	ASTU/L
<input type="checkbox"/> Week 6	ALTU/L
	ASTU/L
<input type="checkbox"/> Week 12	ALTU/L
	ASTU/L
<input type="checkbox"/> Week 24	ALTU/L
	ASTU/L

Perform a test at any time if clinically justified.

If dose increased to **50mg**, restart the monitoring scheme.

<input type="checkbox"/> Initiation of 50mg	ALTU/L
	ASTU/L
<input type="checkbox"/> Week 3	ALTU/L
	ASTU/L
<input type="checkbox"/> Week 6	ALTU/L
	ASTU/L
<input type="checkbox"/> Week 12	ALTU/L
	ASTU/L
<input type="checkbox"/> Week 24	ALTU/L
	ASTU/L

Perform a test at any time if clinically justified.



* Such as dark urine, light coloured stools, yellow skin/eyes, right upper quadrant abdominal pain, sustained new-onset and unexplained fatigue.